Market Dateline PP 7767/09/2010(025354)

RHB Research Institute

RHB Equity 360

17 June 2010 (KPJ, Top Glove; Technical: Titan)

Top Story : KPJ Healthcare Brighter Prospects Ahead Outperform

Visit Note
- For FY09, KPJ recorded a revenue growth of 14.9% yoy largely due to higher contribution from all of its
business segments. Moving forward, we believe KPJs revenue growth drivers include: 1) the opening of at
least two new hospitals p.a.; 2) expansion of its existing hospitals; 3) enhancing its presence in medical
tourism; and 4) higher utilisation rate per patient.
- We understand that KPJ is investing RM200m to build three new hospitals, purchasing of new medical
equipment and expanding its existing hospitals nationwide this year. The construction works for its three
new hospitals which are located in Bandar Baru Klang, Pasir Gudang and Muar have already started and
are due for completion by end of 2011. Management has also plans to increase the beds in its top
performing hospitals i.e. Penang Hospital, Ampang Puteri and Damansara Specialist by 2012.
- Although KPJs focus on positioning itself as a community healthcare provider still remains, the company
realises that there is sizeable growth potential in medical tourism and has identified four hospitals as the
flagship hospitals for its medical tourism segment. However, management mentioned that any significant
contribution from the medical tourism would only come in 3-5 years time. Currently, medical tourism only
accounts for less than 10% of total group revenue.
- We have revised up our FY10-12 earnings forecasts by 9.7-14.3% largely to reflect the upward change in
our revenue assumptions, and lower effective tax rate and MI assumptions.
- Our indicative fair value has been raised to RM4.25 (from RM3.50) based on target FY11 PER of 16x (10%
discount to regional peers average) as we roll forward our valuation year (from FY10). No change to our
Outperform call on the stock.

Corporate Highlights

Top Glove : No Surprises Outperform

Results Note
- Top Gloves 3QFY08/10 net profit of RM64.5m was within our and consensus expectations with 9M net
profit of RM200.2m accounting for 76% of our and consensus full-year estimates respectively.
- Qoq, revenue grew 9.0% as a result of: 1) upward adjustments made to selling prices to pass on the higher
latex cost and weakening US$; and 2) slightly higher sales volume with F20 commencing operations during
the quarter. 3Q10 net profit, however, fell 8.6% qoq due to margin contraction resulting from the time lag in
passing on the higher latex price and weaker US$, partly cushioned by a lower effective tax rate of 21.5%
(vs. 23%) in 2Q10.
- Top Glove declared a tax-exempt DPS of 14 sen (3Q09: 7 sen TE), which translates to a net yield of 1.1%.
We have projected full-year TE DPS of 34 sen, which implies a net payout ratio of 39.3% (FY09: 39.5%)
and net yield of 2.6%.
- Our fair value has been raised to RM16.40 (from RM15.50) based on target FY11 PER of 17x as we roll
forward our valuation year (from CY10). No change to our Outperform call on the stock.

Technical Highlights

Daily Trading Strategy : Technical Pullback Likely To Below 1,300

- Overall, we remain unconvinced on the recent technical rebound, despite the fact that the benchmark has
finally overcome the 1,300 major psychological level yesterday.
- In our view, with the record of a gravestone doji candle, as well as the mixed momentum signals on the
indicators, the FBM KLCI should continue to encounter stiff selling pressure at above or nearer to 1,300.
- In addition, the failure to remove the 40-day SMA at 1,312 yesterday has increased the odds of a technical
pullback risk in the near term.
- This means, unless the index can extend its gains to above the 40-day SMA today, we are of the view that
a technical pullback could happen to drag the index to below the 1,300 psychological level and the 10-day
 SMA near 1,294 soon.
- Further upside resistance is seen at 1,350, should it remove the 40-day SMA unexpectedly.

Daily Technical Watch : Titan Chemicals Corp Outlook will remain positive only if it sustains at above
RM1.35
- 10-day SMA: RM1.369
- 40-day SMA: RM1.284
- Support: IS = RM1.35 S1 = RM1.14 S2 = RM0.80
- Resistance: IR = RM1.51 R1 = RM1.68

Bulletin Board

Co/Sector News Impact Recom

Carlsberg GAB expects sales to increase by 10-15% during We believe that Carlsberg would also record OP, FV =
the 2010 World Cup season vs. 8% in 2006. comparable growth during the World Cup season RM5.85
(Business Times) due to its aggressive A&P activities coupled with
launches of new products. We have already
imputed the sales increase into our earnings
forecasts.

Important Dates

Company Entitlement details Ex-date Payment date

New entitlements
Top Glove Corporation First interim single tier dividend of 14 sen 02-Jul-10 23-Jul-10

Going ex on 18 Jun
Time Engineering Final gross dividend 1.333 sen less 25% tax 18-Jun-10 30-Jun-10
DXN Holdings Fourth interim dividend of 0.75 sen less 25% tax 18-Jun-10 30-Jun-10
Latexx Partners Berhad First interim tax exempt dividend of 2.5 sen 18-Jun-10 5-Jul-10
Stemlife First & final tax-exempt dividend of 10 sen 18-Jun-10 6-Jul-10
Mesiniaga First and final dividend of 19 sen less 25% tax 18-Jun-10 7-Jul-10
Yeo Hiap Seng (M) Final dividend of 6 sen less 25% tax 18-Jun-10 8-Jul-10
Astral Asia First and final dividend of 2 sen less 25% tax 18-Jun-10 8-Jul-10

...For more details, see individual reports attached

IMPORTANT DISCLOSURES

This report has been prepared by RHB Research Institute Sdn Bhd (RHBRI) and is for private circulation only to clients of RHBRI and RHB Investment Bank Berhad (previously known as RHB Sakura Merchant Bankers
Berhad). It is for distribution only under such circumstances as may be permitted by applicable law. The opinions and information contained herein are based on generally available data believed to be reliable and are
subject to change without notice, and may differ or be contrary to opinions expressed by other business units within the RHB Group as a result of using different assumptions and criteria. This report is not to be construed as
an offer, invitation or solicitation to buy or sell the securities covered herein. RHBRI does not warrant the accuracy of anything stated herein in any manner whatsoever and no reliance upon such statement by anyone shall
give rise to any claim whatsoever against RHBRI. RHBRI and/or its associated persons may from time to time have an interest in the securities mentioned by this report.

This report does not provide individually tailored investment advice. It has been prepared without regard to the individual financial circumstances and objectives of persons who receive it. The securities discussed in this
report may not be suitable for all investors. RHBRI recommends that investors independently evaluate particular investments and strategies, and encourages investors to seek the advice of a financial adviser. The
appropriateness of a particular investment or strategy will depend on an investors individual circumstances and objectives. Neither RHBRI, RHB Group nor any of its affiliates, employees or agents accepts any liability for
any loss or damage arising out of the use of all or any part of this report.

RHBRI and the Connected Persons (the RHB Group) are engaged in securities trading, securities brokerage, banking and financing activities as well as providing investment banking and financial advisory services. In the
ordinary course of its trading, brokerage, banking and financing activities, any member of the RHB Group may at any time hold positions, and may trade or otherwise effect transactions, for its own account or the accounts of
customers, in debt or equity securities or loans of any company that may be involved in this transaction.

Connected Persons means any holding company of RHBRI, the subsidiaries and subsidiary undertaking of such a holding company and the respective directors, officers, employees and agents of each of them. Investors
should assume that the Connected Persons are seeking or will seek investment banking or other services from the companies in which the securities have been discussed/covered by RHBRI in this report or in RHBRIs
previous reports.

This report has been prepared by the research personnel of RHBRI. Facts and views presented in this report have not been reviewed by, and may not reflect information known to, professionals in other business areas of
the Connected Persons, including investment banking personnel.

The research analysts, economists or research associates principally responsible for the preparation of this research report have received compensation based upon various factors, including quality of research, investor
client feedback, stock picking, competitive factors and firm revenues.

The recommendation framework for stocks and sectors are as follows : -

Stock Ratings

Outperform = The stock return is expected to exceed the FBM KLCI benchmark by greater than five percentage points over the next 6-12 months.

Trading Buy = Short-term positive development on the stock that could lead to a re-rating in the share price and translate into an absolute return of 15% or more over a period of three months, but fundamentals are not
strong enough to warrant an Outperform call. It is generally for investors who are willing to take on higher risks.

Market Perform = The stock return is expected to be in line with the FBM KLCI benchmark (+/- five percentage points) over the next 6-12 months.

Underperform = The stock return is expected to underperform the FBM KLCI benchmark by more than five percentage points over the next 6-12 months.

Industry/Sector Ratings

Overweight = Industry expected to outperform the FBM KLCI benchmark, weighted by market capitalisation, over the next 6-12 months.

Neutral = Industry expected to perform in line with the FBM KLCI benchmark, weighted by market capitalisation, over the next 6-12 months.

Underweight = Industry expected to underperform the FBM KLCI benchmark, weighted by market capitalisation, over the next 6-12 months.

RHBRI is a participant of the CMDF-Bursa Research Scheme and will receive compensation for the participation. Additional information on recommended securities, subject to the duties of confidentiality, will be made
available upon request.

This report may not be reproduced or redistributed, in whole or in part, without the written permission of RHBRI and RHBRI accepts no liability whatsoever for the actions of third parties in this respect.